Birelentinib

DRUG2 trials

Sponsors

Dizal (Jiangsu) Pharmaceutical Co. Ltd., Dizal Pharmaceuticals

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2

Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

Not yet recruitingNCT07712588

Dizal PharmaceuticalsDiffuse Large B-Cell Lymphoma (DLBCL)

Start: 2027-09-01End: 2032-02-01Target: 880Updated: 2026-07-17

Phase 3

A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 versus Investigator's Choice in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

RecruitingCTIS2025-522669-32-00

Dizal (Jiangsu) Pharmaceutical Co. Ltd.Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start: 2025-12-18Target: 55Updated: 2025-11-13